Meditera Tibbi Malzeme Sanayi ve Ticaret AS engages in manufacturing medical devices. The company was founded on February 14, 1996 and is headquartered in Karabaglar, Turkey.
MEDTR stock has fallen by 2.86% compared to the previous week, the month change is a 4.72% rise, over the last year MEDITERA TIBBI MALZEME has showed a 3.16% increase.
MEDTR net income for the last quarter is 120.24 M TRY, while the quarter before that showed 98.82 M TRY of net income which accounts for 21.67% change. Track more MEDITERA TIBBI MALZEME financial stats to get the full picture.
MEDITERA TIBBI MALZEME dividend yield was 3.15% in 2022, and payout ratio reached 50.50%. The year before the numbers were 7.98% and 83.48% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, MEDTR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDITERA TIBBI MALZEME stock right from TradingView charts — choose your broker and connect to your account.
MEDTR reached its all-time high on Dec 1, 2022 with the price of 48.08 TRY, and its all-time low was 8.72 TRY and was reached on Jul 14, 2021. See other stocks reaching their highest and lowest prices.
As of Apr 26, 2024, the company has 721.00 employees. See our rating of the largest employees — is MEDITERA TIBBI MALZEME on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDITERA TIBBI MALZEME technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDITERA TIBBI MALZEME stock shows the sell signal. See more of MEDITERA TIBBI MALZEME technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.